PRESENTATION

PARTNER WITH US

PRESENTATION

Practical AI Platform

for Disease Risk Stratification.

Predict. Prevent. Transform.

ALZAI transforms routine healthcare data
into disease-specific risk insights,
helping identify high-risk populations earlier
and enabling more targeted clinical action.

THE ALZAI PLATFORM

Turning Routine Healthcare Data Into Disease-Specific Risk Insights

ALZAI’s platform analyzes existing clinical data, applies proprietary AI models, stratifies risk across patient populations and delivers actionable outputs into healthcare workflows.

Routine Healthcare Data

Routine Healthcare Data
EMR Data Lab Results
Clinical History
Demographics

ALZAI AI Platform

Proprietary AI models

Disease-Specific Risk Stratification

Identify elevated risk across populations

Actionable Outputs

Support earlier, more targeted action

DISEASE AREAS

A Growing Portfolio of Disease-Specific Risk Models

Validated models in brain health and liver health, with additional disease areas in development.

BRAIN HEALTH

Alzheimer’s
Disease

AlzAI for Alzheimer’s Disease risk stratification.

Explore AlzAI →

LIVER HEALTH

Liver’s
Disease

LivAI for Liver Disease risk stratification

Explore LivAI →

EXPANDING PORTFOLIO

More Disease Models in Development

Scalable AI architecture for chronic diseases.

View Our Pipeline →

MARKETS

One Platform. Multiple Healthcare Markets.

Our technology supports a wide range of stakeholders across the healthcare ecosystem.

Healthcare Providers

Turn existing healthcare data into predictive insights within clinical workflows.

Health Plans

Support earlier identification, care optimization and risk-adjustment workflows.

Clinical Trials

Identify the right patients earlier and accelerate
recruitment.

Pharma

Identify treatment-eligible populations throughout drug lifecycles.

Longevity

Bring disease-risk insights into preventive and personalized health programs.

NEWS & UPDATES

Stay Up to Date with ALZAI Health

Explore our latest company news, strategic partnerships, research milestones and corporate developments.

Corporate News

September 3, 2026

ALZAI Health Corp. Posted for Trading On The Frankfurt Stock Exchange

Corporate News

August 17, 2026

ALZAI Health Corp. Announces Marketing Services Agreement

Corporate News

August 11, 2026

ALZAI and Linus Health explore AI-driven collaborations aimed at early identification of Alzheimer’s disease risk and cognitive impairment

Corporate News

July 20, 2026

ALZAI Health Corp. Secures Exclusive Global License for AI-Driven Liver Disease Risk Identification Technology

ALZAI transforms routine healthcare data into disease-specific risk insights, helping identify high-risk populations earlier and enabling more targeted clinical action.